VANDA PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
VANDA PHARMACEUTICALS INC. (VNDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-03-31 was $24.00K.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $0.00.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.60M, a 60.98% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-12 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-12 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-12 | |
| 2022-12-31 | $1.60M 10-K · filed 2025-02-14 | |
| 2021-12-31 | $4.10M 10-K · filed 2024-02-08 | |
| 2020-12-31 | $2.90M 10-K · filed 2023-02-09 | |
| 2019-12-31 | $2.50M 10-K · filed 2022-02-24 | |
| 2016-03-31 | $24.00K 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |